NASDAQ:TRAX First Tracks Biotherapeutics Q3 2026 Earnings Results & Report $46.34 +1.29 (+2.86%) Closing price 04:00 PM EasternExtended Trading$46.40 +0.06 (+0.14%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. First Tracks Biotherapeutics beat analyst earnings expectations in its Q3 2026 results, released November 3, 2026. The company reported EPS of -$0.88 versus the -$0.92 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 3, 2026TimeAfter Market ClosesConference Call4:00 PM ET First Tracks Biotherapeutics EPS ResultsActual EPS-$0.88Consensus EPS -$0.92Beat/MissBeat by +$0.04One Year Ago EPSN/AFirst Tracks Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) First Tracks Biotherapeutics Q3 2026 Earnings FAQ Did First Tracks Biotherapeutics beat earnings estimates for Q3 2026? First Tracks Biotherapeutics (NASDAQ:TRAX) reported earnings of -$0.88 per share for Q3 2026, beating the consensus estimate of -$0.92. The report was announced on Tuesday, November 3, 2026. First Tracks Biotherapeutics Earnings HeadlinesFirst Tracks Biotherapeutics Announces Participation in Upcoming Investor ConferencesNovember 3 at 4:15 PM | globenewswire.comFirst Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 3 at 4:15 PM | globenewswire.comThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one recent month, those payments added up to $1,127, without the risks of management decisions or rising mining costs.November 3 at 1:00 AM | Investors Alley (Ad)First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Has Average Price Target of $71.33October 25, 2026 | americanbankingnews.comFirst Tracks Biotherapeutics announces $200M private placementOctober 15, 2026 | msn.comFirst Tracks Biotherapeutics Announces $200 Million Private PlacementOctober 15, 2026 | globenewswire.comSee More First Tracks Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like First Tracks Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on First Tracks Biotherapeutics and other key companies, straight to your email. Email Address About First Tracks BiotherapeuticsFirst Tracks Biotherapeutics (NASDAQ:TRAX) is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.View First Tracks Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Marriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestApple's Earnings Beat Comes With a Catch for Investors Heading Into the HolidaysRepublic Services Has the Momentum, But Waste Management Has Another AdvantageAre the Fears Around Alphabet’s Search Slowdown Warranted?Alphabet's Golden Dome Talks Could Open a New Market, But How Much Is at Stake?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
